Drug Database
Back to search

United Kingdom· GB-APID-39600111000001102

Zolgensma 20 tera vector genomes/ml (patient weight 17.6-18.0kg) solution for infusion 12 x 8.3ml vials

A onasemnogene abeparvovec product containing onasemnogene abeparvovec, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC M09AX09

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedZolgensma 20 tera vector genomes/ml (…ATCM09AX09REGISTER NO.GB-APID-3960011100000…PACKS LISTED2CHECKEDSeptember 13, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about onasemnogene abeparvovecAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Onasemnogene abeparvovec is registered in 14 of 19 countries.

Countries holding a registration under ATC M09AX09 (onasemnogene abeparvovec), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 9 of them publish a price we can compare per daily dose
Search onasemnogene abeparvovec products by name

Onasemnogene abeparvovec · ATC M09AX09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Onasemnogene abeparvovec
Manufacturer
Novartis Pharmaceuticals UK Ltd
Country
United Kingdom (GB)
ATC code
M09AX09
ATC class
Onasemnogene abeparvovec
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    5397227703902
  • gtin
    7612797710326

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

19 interactions on record for onasemnogene abeparvovec.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check onasemnogene abeparvovec against other medicinesHow interaction checks work

Onasemnogene abeparvovec · interactions on record

19 records

  • 4 severe
  • 15 moderate

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Onasemnogene abeparvovec in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All onasemnogene abeparvovec products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Itvisma, Zolgensma
  • Liechtenstein · Itvisma, Zolgensma
  • Norway · Itvisma, Zolgensma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b46d34b1-b15b-4165-87da-b20814ee86fa
GET /v1/drugs/b46d34b1-b15b-4165-87da-b20814ee86fa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "39600111000001102",
  "desc": "Zolgensma 20 tera vector genomes/ml (patient weight 17.6-18.0kg) solution for infusion 12 x 8.3ml vials (Novartis Pharmaceuticals UK Ltd)",
  "form": "Solution for infusion",
  "vpid": "39600611000001105",
  "source": "dmd",
  "vtm_id": "789427008",
  "strength": "20 tera vector genome",
  "substance": "Onasemnogene abeparvovec",
  "ingredient": "Onasemnogene abeparvovec",
  "supplier_code": "2920101000001102"
}
API referenceMCP serverPlans

See everything about onasemnogene abeparvovec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console